ResMed Inc. stock edges lower as analysts lift targets after recent results
Published on 09/20/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. stock (ISIN US7611521078) closed at USD 224.99 on the New York Stock Exchange on September 18, 2026, down 1.50 percent from the previous close, leaving the sleep apnea device maker trading below analysts’ average target after its most recent quarterly results.
Analysts lift ResMed targets after mid-September review
According to Yahoo Finance on September 19, 2026, the consensus analyst price target for ResMed Inc. stands at USD 247.56, roughly 10 percent above the current share price of USD 224.99, indicating moderate upside expectations based on recent coverage.
As Yahoo Finance reports in its analyst overview dated September 15, 2026, RBC Capital upgraded ResMed Inc. from Equal-Weight to Outperform and raised its price target from USD 244 to USD 262, a 7.4 percent increase that reflects greater confidence in the company’s growth and profitability.
Stock trades below 52-week high despite strong rating profile
Based on data from Yahoo Finance as of September 19, 2026, ResMed Inc. shares have traded between a 52-week low of USD 169.71 and a 52-week high of USD 252.39, putting the latest close of USD 224.99 roughly 10.9 percent below the high and 32.6 percent above the low, a range that highlights substantial gains over the past year but leaves room before a new peak.
The same overview from Yahoo Finance shows a market capitalization for ResMed Inc. of around USD 33.5 billion as of September 19, 2026, underlining the company’s status as a large-cap medical technology player in the S&P 500 medical equipment space.
Recent results underpin the investment case
According to ResMed Inc.’s most recent quarterly earnings release for the quarter ended June 30, 2026, the company reported revenue of approximately USD 1.20 billion, up about 12 percent year over year from roughly USD 1.07 billion in the same quarter of 2025, reflecting continued demand for its cloud-connected CPAP devices and masks; this data is summarized on Yahoo Finance.
The same June 30, 2026 quarter figures cited by Yahoo Finance show net income of around USD 260 million versus roughly USD 230 million a year earlier, representing an increase of approximately 13 percent and pointing to operating leverage as revenue expands.
For that June 30, 2026 quarter, diluted earnings per share reached about USD 1.77 compared with nearly USD 1.56 in the prior-year period, a gain of roughly 13 percent that helps explain why several research providers list ResMed Inc. with a Buy or Outperform rating, as reflected in the analyst rating breakdown on Yahoo Finance.
Risk factors and valuation considerations
While the rating profile is supportive, ResMed Inc. stock’s valuation metrics are elevated relative to some peers in the medical equipment segment, with the price-to-earnings ratio for the trailing twelve months above 30 times according to Yahoo Finance, a level that leaves limited room for disappointment if growth slows.
Another key risk highlighted by analysts in the aggregated recommendations on Yahoo Finance is continued competition in sleep and respiratory care, where rival devices and changing reimbursement rules could weigh on margins even as ResMed invests heavily in software and data platforms.
ResMed Inc. stock price level as of the last close
ResMed Inc. stock last closed at USD 224.99 on the New York Stock Exchange on September 18, 2026, after a daily decline of USD 3.43 or 1.50 percent, with trading volume of 610,433 shares recorded for that session, positioning the shares below both the RBC Capital target of USD 262 and the broader analyst average target of USD 247.56 and leaving investors focused on whether upcoming quarters can sustain double-digit revenue and earnings growth.
ResMed Inc. stock facts
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Trading venue: NYSE
- Price (as of September 18, 2026, 16:00): 224.99 USD
- Market capitalization: 33,500,000,000 USD (as of September 19, 2026)
- Sector / Industry: Health Care / Medical Equipment
- Index membership: S&P 500
